Innovation Pte. Ltd. 6/ Others items and elimination As for the performance of the first 9 months of 2018, Bangchak Corporation Plc. (“The Company”) and its subsidiaries recorded revenue from sale of goods and
PUBLIC COMPANY LIMITED BANGKOK DEC - CON PUBLIC COMPANY LIMITED BANGKOK DUSIT MEDICAL SERVICES PUBLIC COMPANY LIMITED BANGKOK EXPRESSWAY AND METRO PUBLIC COMPANY LIMITED BANGKOK GENOMICS INNOVATION PUBLIC
BANGKOK DUSIT MEDICAL SERVICES PUBLIC COMPANY LIMITED BANGKOK EXPRESSWAY AND METRO PUBLIC COMPANY LIMITED BANGKOK EXPRESSWAY PUBLIC COMPANY LIMITED BANGKOK GENOMICS INNOVATION PUBLIC COMPANY LIMITED BANGKOK
livestock animal products, together with a rise in revenues from sales of healthcare products and aesthetic innovation products for human from Baht 224.58 million in 2018 to Baht 229.87 million or 2.36% in
ZIGA Innovation Public Company Limited ("the Company") would like to clarify operating performance of the Company three-month for the Quarter 2/2017 and consolidated financial statements ended 30th June
วิทยาศาสตร์และเทคโนโลยีทำหน้าที่ในการพัฒนาเศรษฐกิจและสังคมของประเทศได้อย่างแท้จริง?นายชนิตร ชาญชัยณรงค์? รองผู้จัดการ สายงานผู้ออกหลักทรัพย์และบริษัทจดทะเบียน ตลาดหลักทรัพย์แห่งประเทศไทย กล่าวว่า ?Innovation
company and the unitholders; (7) the money borrowing or creation of encumbrances on a fund’s assets; (8) the liquidation of a fund. In the case where no specific notifications prescribe the rules related to
prevention of conflicts of interest between the management company and the unitholders; (7) the money borrowing or creation of encumbrances on a fund ’s assets; (8) the liquidation of a fund . In the case